Skip to content
Clinical Trials – home
Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on two chronic intestinal conditions, Crohn's Disease and Ulcerative Colitis. These diseases cause inflammation of the digestive tract, leading to abdominal pain, diarrhea, and weight loss. The treatments being tested include a drug called risankizumab, an injectable medicine that targets specific immune cells, and a second agent named ABBV-701, also given by injection. A combination product identified as ABBV-7066 (risankizumab/ABBV-701) will be evaluated together, as well as each medication alone and a placebo.

The purpose of the study is to compare how well the combination works against the individual medicines in adults with moderately to severely active disease. Participants will receive a series of subcutaneous injections (a shot under the skin) or an intravenous infusion (medicine delivered through a vein) over several weeks. During the trial, doctors will look inside the intestine using a camera (endoscopy) to see if the lining has healed, a state called endoscopic remission, and will also record symptoms such as stool frequency and abdominal pain to assess clinical improvement.

Throughout the study, participants will be monitored for any side effects, referred to as adverse events, and will have regular visits to check their health status. The overall study period lasts several months, allowing researchers to gather information on both safety and how effectively the medicines reduce disease activity.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Visit and Randomization

    You will attend a baseline visit after you have joined the study. During this visit, the study staff will confirm that you meet all eligibility requirements and will assign you to one of the treatment groups. The groups include a combination of ABBV-701 and risankizumab, each medication given alone, or a matching placebo. The assigned medication will be prepared for administration according to the study protocol.

    The first dose of the assigned medication will be given on the same day. ABBV-701 is administered by subcutaneous injection (injection under the skin). Risankizumab may be given either by subcutaneous injection or by intravenous infusion (drip into a vein). The exact dose is specified in the study protocol.

  2. Step 2

    Regular Treatment Administration

    You will receive additional doses of the assigned medication at scheduled intervals for a total treatment period of approximately 28 weeks. The schedule follows the study protocol and may involve injections or infusions every few weeks. Each administration follows the same route (subcutaneous injection or intravenous infusion) as the first dose.

    If you are assigned to a placebo group, you will receive an injection or infusion that looks identical to the active medication but contains no therapeutic substance.

  3. Step 3

    Week 12 Assessment

    At week 12, you will return for a study visit that includes an endoscopic examination. This procedure allows the doctor to look inside your intestine to determine whether you have achieved endoscopic remission (no visible inflammation).

    The visit also includes clinical assessments such as symptom questionnaires and safety checks for any adverse events (possible side effects). Results from these assessments help evaluate the effectiveness of the treatment at the midpoint of the study.

  4. Step 4

    Week 28 Final Assessment

    At week 28, you will attend the final study visit. Another endoscopic examination will be performed to assess whether you have achieved endoscopic remission at the end of the study. Additional clinical evaluations will be conducted to measure disease activity and record any adverse events that occurred during the trial.

    These final results are used to compare the combination therapy, each monotherapy, and placebo in terms of efficacy and safety.

  5. Step 5

    Study Completion

    After the week 28 visit, the study medication will be discontinued. You will receive information about any follow‑up care that may be needed, and the study team will document the overall outcome of your participation.

Who can join the trial?

9 criteria

  • Must be an adult (18 years of age or older).
  • Must have a confirmed diagnosis of Crohn's Disease that was made at least 90 days before the start of the study.
  • Must have a Crohn's Disease Activity Index (CDAI) score of 220 or higher, which means the disease is moderately to severely active.
  • Must have endoscopic evidence of intestinal inflammation, shown by a Simple Endoscopic Score for Crohn's Disease (SES‑CD) of 6 or more if the disease involves the colon or both colon and ileum, or a score of 4 or more if only the ileum is affected.
  • Must have tried at least one medication or other therapy for Crohn's Disease that did not work well enough (treatment failure).
  • Must have a confirmed diagnosis of Ulcerative Colitis that was made at least 90 days before the start of the study.
  • Must have active Ulcerative Colitis with a modified Mayo Score (mMS) between 5 and 9 and an endoscopic subscore (ESS) of 2 or 3, indicating moderate to severe disease.
  • Must have tried at least one medication or other therapy for Ulcerative Colitis that did not work well enough (treatment failure).
  • Both men and women are eligible to take part in the study.

Who cannot join the trial?

8 criteria

  • People who are known to be unable to tolerate p19 IL‑23 inhibitors (a type of medicine that includes risankizumab) cannot join the study.
  • Anyone who has taken another experimental medicine within the last 30 days, or for a period longer than five times the drug’s half‑life (the time it takes for half of the drug to leave the body), is not allowed to participate.
  • Participants who have used any other advanced therapies, such as biologics (large protein medicines) or small‑molecule drugs, within the time frame set by the study protocol cannot be enrolled.
  • People who have had surgery to remove part of their bowel (known as a surgical bowel resection) in the three months before the study starts are excluded.
  • For those with Crohn’s Disease, having had more than three previous bowel surgeries makes them ineligible.
  • For those with Crohn’s Disease, having had a small‑bowel surgery that removed more than 100 cm (about the length of a ruler) of intestine also disqualifies them.
  • For those with Ulcerative Colitis, anyone who has already had a total or partial removal of the colon (called a colectomy) cannot take part.
  • For those with Ulcerative Colitis, if the disease affects only a very short segment—less than 10 cm of the rectum (the lowest part of the intestine)—the person is not eligible.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

ABBV-701
ABBV-701 is an experimental medicine being studied for inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. It is given as a small injection under the skin (subcutaneous injection). In the trial it is tested to see if it can reduce gut inflammation and improve symptoms when used alone or together with another drug.

ABBV-066 (risankizumab)
ABBV-066, known by its international name risankizumab, is a type of biologic drug called a monoclonal antibody. It works by blocking a protein that drives inflammation in the intestine. In this study it is administered as a pre‑filled syringe that is injected under the skin. The goal is to see how well it can calm the immune system and help patients feel better.

Risankizumab (intravenous infusion)
The same risankizumab molecule can also be given through an IV (intravenous) infusion, where the medication is delivered directly into a vein over a short period of time. This form is included in the trial to compare how the method of delivery (injection under the skin versus IV infusion) might affect its safety and effectiveness.

Combination of ABBV-701 and ABBV-066 (risankizumab)
The study also tests a combination therapy that uses both ABBV-701 and ABBV-066 together. Researchers want to know whether using the two medicines at the same time works better than using each one alone in reducing the inflammation that causes Crohn’s disease or ulcerative colitis. The combination is given by the same routes described above (subcutaneous injection for each drug).

What is already known about the treatment

  • ABBV-701

    This medication is given as a subcutaneous injection in a clear solution for injection. It is an investigational drug that is currently being studied in clinical trials and is not yet approved for routine medical use. The trial is testing it for adults with moderately to severely active Crohn’s disease or ulcerative colitis, either alone or together with another drug. ABBV‑701 works by targeting a specific protein that helps control inflammation, and it belongs to the class of experimental biologic therapies.

  • Risankizumab

    Risankizumab is administered either as a subcutaneous injection or as an intravenous infusion, both using a sterile solution prepared for injection. It is an approved monoclonal antibody that blocks the interleukin‑23 (IL‑23) protein, reducing the inflammatory signals that drive disease. The drug is used to treat moderate to severe Crohn’s disease and ulcerative colitis, and it is classified as an immunosuppressive biologic agent. In the study it is examined both alone and in combination with ABBV‑701 to see if the combination works better.

Investigated diseases

  • Crohn's Disease

    Crohn's disease is a chronic condition that causes inflammation of the digestive tract, often affecting the end of the small intestine and the beginning of the colon. The inflammation may spread deep into the layers of the bowel wall, leading to pain, diarrhea, and weight loss. Over time, the affected areas can become narrowed or develop abnormal connections called fistulas. Symptoms may come and go, with periods of worsening followed by quieter phases. The disease can involve any part of the gastrointestinal tract, so its pattern of spread varies between individuals.

  • Ulcerative Colitis

    Ulcerative colitis is a long‑lasting disorder that inflames the lining of the large intestine, starting in the rectum and potentially extending upward through the colon. The inflamed lining develops tiny sores that cause frequent, urgent bowel movements and blood in the stool. As the condition continues, the colon may become thinner and lose its normal shape, leading to more frequent symptoms. The disease typically follows a pattern of flare‑ups and periods of relative calm. It is limited to the colon and does not affect other parts of the digestive system.

Trial detailsLast updated 19 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-525960-16-00Protocol codeM26-266-2Estimated enrolment749 patientsSponsorAbbVie Deutschland GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.